Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Ho, Anthony D  [Clear All Filters]
2014
Schmitt T, Goldschmidt H, Neben K, Freiberger A, Hüsing J, Gronkowski M, Thalheimer M, Pelzl LHang, Mikus G, Burhenne J, et al. Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial. J Clin Oncol. 2014.
Stiehl T, Ho AD, Marciniak-Czochra A. Assessing Hematopoietic (Stem-) Cell Behavior During Regenerative Pressure. Adv Exp Med Biol. 2014;844:347-367.
Radujkovic A, Luft T, Dreger P, Ho AD, W Zeller J, Fruehauf S, Topaly J. In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia. Cancer Chemother Pharmacol. 2014.
Nicolay NH, Sommer E, Perez RLopez, Wirkner U, Bostel T, Ho AD, Lahn M, Debus J, Saffrich R, Huber PE. Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation. Strahlenther Onkol. 2014.
Dietrich S, Radujkovic A, Stölzel F, Falk CS, Benner A, Schaich M, Bornhäuser M, Ehninger G, Krämer A, Hegenbart U, et al. Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. Transplantation. 2014.
Rachakonda SP, Penack O, Dietrich S, Blau O, Blau IWolfgang, Radujkovic A, Isermann B, Ho AD, Uharek L, Dreger P, et al. Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease. J Clin Oncol. 2014.